Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol Metered Dose Inhaler in COPD.

@article{Martinez2017BaselineSS,
  title={Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol Metered Dose Inhaler in COPD.},
  author={Fernando J Martinez and Leonardo M Fabbri and Gary Thomas Ferguson and Chad Orevillo and Patrick F Darken and U. S. A. James Martin and Colin Reisner},
  journal={Chest},
  year={2017},
  volume={152 6},
  pages={1169-1178}
}
BACKGROUND The clinical severity of COPD is currently categorized by symptom burden and exacerbation risk. Previous 24-week phase III trials (NCT01854645 and NCT01854658) that demonstrated better improvement of lung function with glycopyrrolate/formoterol fumarate (GFF) metered dose inhaler (MDI) (an MDI fixed-dose of GFF 18/9.6 μg) over individual monocomponent MDIs included a cross-section of patients with moderate to very severe airflow limitation and a broad range of COPD symptoms… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 31 times over the past 90 days. VIEW TWEETS
2 Citations
30 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 30 references

Effect Of Bronchodilator And Placebo Therapy On SGRQ Score In COPD Patients Over 3 Years: Difference Between Low/Medium And High Socio-Economic Countries

  • PW Jones, HL Gelhorn, H Wilson
  • Available at http://www.atsjournals.org/doi/abs…
  • 2017
1 Excerpt

The novel LAMA/LABA Co-Suspension TechnologyTM of glycopyrrolate/formoterol fixed-dose combination MDI significantly improves health status in symptomatic patients with COPD [abstract

  • FJ Martinez, LM Fabbri, GT Ferguson, C Orevillo, P Darken, C. Reisner
  • Am J Respir Crit Care Med
  • 2016

Similar Papers

Loading similar papers…